title: Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site.
abstract: Viral neuraminidase inhibitors such as oseltamivir and zanamivir prevent early virus multiplication by blocking sialic acid cleavage on host cells. These drugs are effective for the treatment of a variety of influenza subtypes, including swine flu (H1N1). The binding site for these drugs is well established and they were designed based on computational docking studies. We show here that some common natural products have moderate inhibitory activity for H1N1 neuraminidase under docking studies. Significantly, docking studies using AutoDock for biligand and triligand forms of these compounds (camphor, menthol, and methyl salicylate linked via methylene bridges) indicate that they may bind in combination with high affinity to the H1N1 neuraminidase active site. These results also indicate that chemically linked biligands and triligands of these natural products could provide a new class of drug leads for the prevention and treatment of influenza. This study also highlights the need for a multiligand docking algorithm to understand better the mode of action of natural products, wherein multiple active ingredients are present.
authors: Centre for Chemistry and Biotechnology, Deakin University, Geelong, VIC, Australia ; Bigtec Pvt Ltd, Rajajinagar, Bangalore, India.
authors: Manoj M
authors: MM
authors: Narayanan
authors: Chandrasekhar B
authors: CB
authors: Nair
authors: Shilpa K
authors: SK
authors: Sanjeeva
authors: Pv Subba
authors: PS
authors: Rao
authors: Phani K
authors: PK
authors: Pullela
authors: Colin J
authors: CJ
authors: Barrow
keywords: H1N1; binding energy; influenza; molecular docking; multiligand; neuraminidase; virus
references: PLoS One. 2012;7(9):e44057
references: 22970161
references: J Chem Inf Model. 2012 Oct 22;52(10):2715-29
references: 22998323
references: Expert Opin Drug Saf. 2009 May;8(3):357-71
references: 19355841
references: J Comput Chem. 2004 Oct;25(13):1605-12
references: 15264254
references: PLoS One. 2011 Feb 07;6(2):e16284
references: 21326879
references: J Comput Chem. 2009 Dec;30(16):2785-91
references: 19399780
references: Antivir Ther. 2007;12(4 Pt B):593-602
references: 17944267
references: Ther Clin Risk Manag. 2007 Jun;3(3):461-5
references: 18488077
references: Nat Struct Mol Biol. 2008 Jul;15(7):690-8
references: 18596815
references: Clin Infect Dis. 2010 Oct 15;51(8):887-94
references: 20815736
references: Chem Biol. 2004 Feb;11(2):185-94
references: 15123280
references: EMBO J. 1992 Jan;11(1):49-56
references: 1740114
references: Virol J. 2009 May 07;6:51
references: 19422701
references: Protein Sci. 2009 Apr;18(4):707-15
references: 19309695
references: J Ethnopharmacol. 2007 Jun 13;112(2):341-9
references: 17459623
references: J Virol. 2008 Nov;82(21):10493-501
references: 18715929
references: Nature. 2006 Sep 7;443(7107):45-9
references: 16915235
references: Protein Sci. 1994 Oct;3(10):1687-96
references: 7849585
references: Nat Rev Drug Discov. 2006 Dec;5(12):1015-25
references: 17139286
references: Biol Direct. 2009 May 20;4:18; discussion 18
references: 19457254
references: Nature. 2008 Jun 26;453(7199):1258-61
references: 18480754